Irlanti - englanti - HPRA (Health Products Regulatory Authority)

unichem laboratories ltd - bisoprolol hemifumarate - tablet - 10 milligram(s) - beta blocking agents, selective; bisoprolol

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

unichem laboratories ltd - bisoprolol fumarate - tablet - 5 milligram(s) - beta blocking agents, selective; bisoprolol

Yhdysvallat - englanti - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti), chlorthalidone (unii: q0mqd1073q) (chlorthalidone - unii:q0mqd1073q) - atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. this fixed dose combination drug is not indicated for initial therapy of hypertension. if the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. atenolol and chlorthalidone tablets are contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (see warnings ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs.

Yhdysvallat - englanti - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - guanfacine (unii: 30omy4g3mk) (guanfacine - unii:30omy4g3mk) - guanfacine tablets are indicated in the management of hypertension. guanfacine tablets may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. guanfacine tablets are contraindicated in patients with known hypersensitivity to guanfacine hydrochloride. no reported abuse or dependence has been associated with the administration of guanfacine hydrochloride.

Yhdysvallat - englanti - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride tablets, usp are indicated in the management of hypertension. labetalol hydrochloride tablets, usp may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hydrochloride is contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings ). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Yhdysvallat - englanti - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - hydrochlorothiazide 6.25 mg - bisoprolol fumarate and hydrochlorothiazide tablets are indicated in the management of hypertension. bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see warnings), second or third degree av block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

Yhdysvallat - englanti - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - bisoprolol fumarate 5 mg - bisoprolol fumarate is indicated in the management of hypertension. it may be used alone or in combination with other antihypertensive agents. bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree av block, and marked sinus bradycardia.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

unichem laboratories ltd - fluoxetine hydrochloride - capsule, hard - 20 milligram(s) - selective serotonin reuptake inhibitors; fluoxetine

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

unichem laboratories ltd - bisoprolol fumarate - tablet - 2.5 milligram(s) - beta blocking agents, selective; bisoprolol

Yhdysvallat - englanti - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride tablets, usp are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets, usp has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, usp relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association's diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: - motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. - autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. - apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. - vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling "on edge," irritability, impatience. the above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. however, mild depressive symptoms are common in gad. the effectiveness of buspirone hydrochloride tablets, usp in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad. however, in a study of long-term use, 264 patients were treated with buspirone hydrochloride tablets, usp for 1 year without ill effect. therefore, the physician who elects to use buspirone hydrochloride tablets, usp for extended periods should periodically reassess the usefulness of the drug for the individual patient. buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. the use of monoamine oxidase inhibitors (maois) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. the use of buspirone within 14 days of stopping an maoi intended to treat depression is also contraindicated. starting buspirone in a patient who is being treated with reversible maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings , dosage and administration and drug interactions ). buspirone hydrochloride is not a controlled substance. in human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence. human volunteers with a history of recreational drug or alcohol usage were studied in two double-blind clinical investigations. none of the subjects were able to distinguish between buspirone hydrochloride tablets and placebo. by contrast, subjects showed a statistically significant preference for methaqualone and diazepam. studies in monkeys, mice, and rats have indicated that buspirone lacks potential for abuse. following chronic administration in the rat, abrupt withdrawal of buspirone did not result in the loss of body weight commonly observed with substances that cause physical dependency. although there is no direct evidence that buspirone hydrochloride tablets cause physical dependence or drug-seeking behavior, it is difficult to predict from experiments the extent to which a cns-active drug will be misused, diverted, and/or abused once marketed. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of buspirone hydrochloride tablets misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).